Business Overview
VIVUS is a development stage company that researches advanced therapeutic systems for impotence, which affects an estimated 30% of males between the ages of 40 and 70. The company's Medicated Urethral System for Erection (MUSE) is a noninvasive, easy-to-use system that delivers topical pharmaceuticals via the urethra. The company's first product, MUSE-alprostadil, which is still in clinical trials, is a small, single-use disposable plastic applicator that dispenses a synthetic version of a naturally occurring hormone, prostaglandin, to achieve penile rigidity within 15 minutes of administration. The effect lasts approximately 30-60 minutes.
as per market Guide, insiders own 33.94%
<as of 12-5-97> institutions hold 65.32%
3 Lists, Insider BUYS, Insider sales, and Insider Form 144's:
VVUS insider buys:
NONE for year; any month.
Insider sales:
month $ amount #shares by who date avg price
Jan NONE
Feb NONE
Mar 7,139,407 112,997 7-DDOOOCP 2-3 to 2-26 63.18
Apr NONE
May 241,766 5,708 2-DP 4-15 to 4-18 42.36
June NONE
July NONE
Aug 4,116,015 136,833 6-DSDCPF 30.08
Sep NONE
Oct 214,000 8,000 1-O 8-29 26.75
Nov 714,850 20,000 2-VF 10-13 35.74
Dec <to date> NONE
Form 144's:
Jan NONE
Feb 2,715,790 53,160 5-ADAUU 51.09
Mar 2,868,509 39,837 6-DDAAAA 72.01
Apr 569,329 10,708 3-DFT 53.17
May NONE
Jun 59,000 1,283 1-S 45.99
July 3,399,375 115,000 6-DDFDCP 29.56
Aug 1,509,021 51,833 2-DU 29.11
Sep 4,892,812 164,306 4-NDAS 29.78
Oct NONE
Nov 250,000 10,000 1-A 25.00
Dec<to date> NONE |
